#CRAVAT Report
#Created at Monday 10/19/2020 10:54:08
#Report level: variant
#
Variant Annotation																Cancer Genome Interpreter					
UID	Chrom	Position	Ref Base	Alt Base	Note	Coding	Gene	Transcript	Sequence Ontology	cDNA change	Protein Change	All Mappings	Sample Count	Samples	Tags	Association	Biomarker	Drug	Evidence	Source	Tumor Type
1	chr14	105243048	G	T			BRF1	ENST00000547530.7	intron_variant	c.545-1634C>A		ENST00000327359.7:BRF1:Q92994:intron_variant::c.200-1634C>A; ENST00000379932.8:BRF1::intron_variant::c.-68-1634C>A; ENST00000379937.6:BRF1:Q92994:intron_variant::c.464-1634C>A; ENST00000392557.8:BRF1:Q92994:intron_variant::c.-68-1634C>A; ENST00000440513.7:BRF1:Q92994:intron_variant::c.200-1634C>A; ENST00000446501.6:BRF1:Q92994:intron_variant::c.-21+6101C>A; ENST00000547530.7:BRF1:Q92994:intron_variant::c.545-1634C>A; ENST00000551787.5:BRF1::intron_variant::c.-68-1634C>A; ENST00000619151.4:BRF1::intron_variant::c.-68-1634C>A	1	s0		Resistant	AKT1 (Q79K,E17K)	BRAF inhibitors	Case report	PMID:24265152	Cutaneous melanoma
2	chr9	133748415	T	G									1	s1		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	Bosutinib (BCR-ABL inhibitor  3rd gen)	NCCN guidelines	PMID:21562040	Chronic myeloid leukemia
3	chr2	29443642	C	G			ALK	ENST00000389048.8	intron_variant	c.1155-59783G>C		ENST00000389048.8:ALK:Q9UM73:intron_variant::c.1155-59783G>C; ENST00000618119.4:ALK::intron_variant::c.24-59783G>C	1	s2		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	Crizotinib (ALK inhibitor)	Pre-clinical	PMID:22072639	Glioma
4	chr7	116417457	G	A			AC002066.1	ENST00000439070.1	lnc_RNA			ENST00000439070.1:AC002066.1::intron_variant,lnc_RNA::; ENST00000446355.2:AC002066.1::intron_variant,lnc_RNA::; ENST00000462876.5:CAV2::intron_variant,processed_transcript::; ENST00000467035.5:CAV2::intron_variant,processed_transcript::; ENST00000472470.5:CAV2::intron_variant,processed_transcript::; ENST00000477018.5:CAV2::intron_variant,processed_transcript::; ENST00000478226.5:CAV2::intron_variant,processed_transcript::; ENST00000484871.5:CAV2::intron_variant,processed_transcript::; ENST00000485561.5:CAV2::intron_variant,processed_transcript::; ENST00000498493.5:CAV2::intron_variant,processed_transcript::; ENST00000656866.1:AC002066.1::intron_variant,lnc_RNA::	1	s3		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Crizotinib (ALK inhibitor)	Pre-clinical	PMID:17483355	Any cancer type
5	chr1	111762684	G	A		Yes	DDX20	ENST00000369702.5	missense_variant	c.1112G>A	p.Arg371His	ENST00000369702.5:DDX20:Q9UHI6:missense_variant:p.Arg371His:c.1112G>A; ENST00000475700.1:DDX20::5_prime_UTR_variant::c.-188G>A; ENST00000533164.5:DDX20:Q9UHI6:NMD_transcript_variant,3_prime_UTR_variant::c.*526G>A	1	s4							
#CRAVAT Report
#Created at Monday 10/19/2020 10:54:08
#Report level: gene
#
Variant Annotation					
Gene	Note	Number of Coding Variants	Number of Noncoding Variants	Sequence Ontology	All Sequence Ontologies
BRF1		0	1	intron_variant	intron_variant(1)
ALK		0	1	intron_variant	intron_variant(1)
AC002066.1		0	1	lnc_RNA	intron_variant(1),lnc_RNA(1)
DDX20		1	0	missense_variant	missense_variant(1),NMD_transcript_variant(1),3_prime_UTR_variant(1),5_prime_UTR_variant(1)
#CRAVAT Report
#Created at Monday 10/19/2020 10:54:08
#Report level: sample
#
Variant Annotation	
UID	Sample
1	s0
2	s1
3	s2
4	s3
5	s4
#CRAVAT Report
#Created at Monday 10/19/2020 10:54:08
#Report level: mapping
#
Variant Annotation			
Original Line	User Tags	UID	Input File Number
1		1	0
2		2	0
3		3	0
4		4	0
5		5	0
